



MISSISSIPPI DIVISION OF
MEDICAID

**MISSISSIPPI DIVISION OF MEDICAID
Pharmacy & Therapeutics Committee Meeting**

Woolfolk Building
Conference Center East, Room 145
Jackson, MS 39201-1399

**October 22, 2019
9:00am to 5:00pm**

MINUTES

Committee Members Present:

Logan Davis, PharmD, MBA
Clyde E. Glenn, MD
D. Stanley Hartness, MD
Karen Maltby, MD
Deborah Minor, PharmD, Co-Chair
Kim Rodgers, RPh
Spencer Sullivan, MD
Geri Lee Weiland, MD
Wilma Wilbanks, RPh, Chair

Committee Members Not Present:

James B. Brock, MD
Mack Woo, MD

Division of Medicaid Staff Present:

Terri Kirby, RPh, CPM, Pharmacy Director
Carlos Latorre, MD, Medical Director
Cindy Noble, PharmD, MPH, Pharmacist III
Drew Snyder, Executive Director
Chris A. Yount, MA, PMP, Staff Officer III

CHC Staff Present:

Sarah Boydstun, PharmD
Paige Clayton, PharmD
Robert Dinwiddie, PharmD
James "Rusty" Hailey, PharmD, DPh,
MBA, FAMCP
Jacquelyn Hedlund, MD, MS
Shannon Hardwick, RPh
Steve Liles, PharmD

Other Contract Staff Present:

Catherine Brett, MD, Alliant
Jenni Grantham, PharmD, Magnolia
Heather Odem, PharmD, UHC
Eric Pittman, PharmD, UMC School of
Pharmacy
Lew Anne Snow, RN, Conduent
Trina Stewart, PharmD, Molina
Michael Todaro, PharmD, Magnolia

Mississippi Pharmacy & Therapeutics Committee Meeting Minutes
October 22, 2019

Attendance Chart:

Committee Member	AUG 2019	OCT 2019	FEB 2019	MAY 2019
Brock	x			
Davis	x	x		
Glenn	x	x		
Hartness	x	x		
Maltby	x	x		
Minor	x	x		
Rodgers	x	x		
Sullivan	x	x		
Weiland		x		
Wilbanks		x		
Williamson	x	x		
Woo	x			

I. Call to Order

Mrs. Wilbanks, chair, called the meeting to order at 9:06 a.m.

II. Introductions

Ms. Terri Kirby, Mississippi Division of Medicaid (DOM) Pharmacy Director, welcomed the Pharmacy & Therapeutics (P&T) Committee and all guests in the audience.

She introduced Change Healthcare, DOM's Preferred Drug List (PDL) and Supplemental Rebate (SR) vendor. All parties seated at the table introduced themselves and gave a brief statement about their professional credentials and affiliations.

Ms. Kirby introduced DOM staff members Chris Yount, Joyce Hunter and Jessica Tyson. Ms. Kirby recognized DOM contractors in the audience, including Lew Anne Snow from Conduent, Dr. Trina Stewart from Molina Health Systems, Drs. Jenni Grantham and Michael Todaro from Magnolia Health Plan, Dr. Heather Odem from United Healthcare, Dr. Eric Pittman from the UMC School of Pharmacy DUR and Drs. Sarah Boydston, Robert Dinwiddie, Rusty Haley and Shannon Hardwick from Change Healthcare and Dr. Catherine Britt from Alliant. She also introduced the Division of Medicaid Medical Director, Dr. Carlos Latorre.

III. Administrative Matters

Ms. Kirby reminded guests to register prior to each P&T Committee meeting via the electronic process available through the DOM website (www.medicaid.ms.gov). She stated that copies of the agenda and the public comment guidelines are available at the industry sign-in table. She stated that there is a separate sign in sheet for advocates and reminded guests that advocate presenters are limited to 3 minutes of general comment about a disease, not specific to a drug. She noted that industry presenters must provide their full name, drug name, identification, and company affiliation when signing in. She stated that industry presenters are allowed 3 minutes per drug and that no handouts are permitted. Presenters are requested to sign in at least 10 minutes prior to start of meeting.

Ms. Kirby stated that any documents used in the meeting that are not marked confidential and proprietary will be posted on DOM's website (www.medicaid.ms.gov) after the meeting.

Ms. Kirby reviewed policies related to food and drink, cell phones and laptop usage, discussions in the hallways, and emergency procedures for the building.

Ms. Kirby stated that DOM aggressively pursues supplemental rebates. Mississippi is part of the Sovereign States Drug Consortium (SSDC) pool.

Ms. Kirby reviewed the voting procedure and reminded the Committee that, in accordance with the Mississippi Open Meetings Act, the minutes reflect each person's vote. She requested that the Chair announce the recommendation, motions, and the names of committee members making motions. The minutes for each P&T Committee meeting are posted to the DOM website (www.medicaid.ms.gov) within 30 days of the meeting. The meeting minutes will be posted no later than November 21, 2019. The PDL decisions will be announced no later than December 1, 2019 on the DOM website.

Ms. Kirby stated that the P&T Committee works in an advisory capacity and that DOM is responsible for final decisions related to the PDL. She reviewed the meeting process. She stated that DOM takes into account recommendations from both the P&T Committee and the clinical contractor before making a final decision. She stated that the PDL is completely updated once per year; quarterly updates are implemented throughout the year.

Ms. Kirby reviewed Committee policies and procedures. She requested that Committee members complete their travel vouchers and reviewed the contents of the folders provided to each Committee member.

IV. Approval of August 13, 2019 Meeting Minutes

Mrs. Wilbanks asked for additions or corrections to the minutes from the August 13, 2019 meeting. There were no further additions or corrections. The minutes stand approved..

V. PDL Compliance/Generic Percent Report Updates

Dr. Clayton provided an explanation of the PDL Compliance and Generic Percent reports.

- A.** Dr. Clayton reviewed the PDL Compliance Report; overall compliance for Q3 2019 was 97.1%.
- B.** Dr. Clayton reviewed the Generic Percent Report; overall generic utilization for Q3 2019 was 87.7%.

VI. Drug Class Announcements

Dr. Clayton reviewed the meeting format. Dr. Clayton also stated that the Division of Medicaid made 3 off cycle changes to the PDL. Those changes were moving branded Lyrica, branded Epclusa and chewable cetirizine to non-preferred, effective November 1, 2019

VII. First Round of Extractions

Change Healthcare recommended that the following classes be extracted:

- Antiretrovirals
- Bronchodilators & COPD Agents
- Bronchodilators, Beta Agonists
- Factor Deficiency Products
- Glucocorticoids (Inhaled)
- Hypoglycemics, Insulins & Related Agents
- Opiate Dependence Treatments
- Pulmonary Antihypertensives
- Stimulants & Related Agents

VIII. Public Comments

1. Alice Kelly Morgan from Pfizer spoke in favor of Eucrisa.
2. Deb Chatterjee from Eisai spoke in favor of Fycompa.
3. Karen Campbell from Amgen spoke in favor of Repatha and Aimovig.
4. Joseph Goble from Janssen Scientific Affairs, LLC spoke in favor of Invokana and Tremfya.
5. Michael Nelson from Sunovion spoke in favor of Latuda and Aptiom.
6. William Mullen from Indivior spoke in favor of Perseris and Sublocade.
7. Danielle Wiley from Neurocrine Biosciences spoke in favor of Ingrezza (valbenazine).
8. Robert Welch from Greenwich Biosciences spoke in favor of Epidiolex (cannabidiol oral solution).
9. Dina Besece from Paratek spoke in favor of Omadacycline (Nuzyra).
10. Nathaniel Cashion from Genentech spoke in favor of Hemlibra (emicizumab).

IX. Second Round of Extractions

Change Healthcare and the Committee recommended that the following categories be extracted:

- Dr. Weiland extracted the Atopic Dermatitis Class

X. Motion for All Non-Extracted Categories to be Approved as Proposed

Change Healthcare recommended that the following list of classes be approved without extraction:

- | | |
|---------------------------------------|-------------------------------|
| • Acne Agents | • Angiotensin Modulators |
| • Alpha1-Proteinase Inhibitor | • Antibiotics (GI) |
| • Alzheimer's Agents | • Antibiotics (Miscellaneous) |
| • Analgesics, Narcotics- Short Acting | • Antibiotics (Topical) |
| • Analgesics, Narcotics- Long Acting | • Antibiotics (Vaginal) |
| • Analgesics/Anesthetics (Topical) | • Anticoagulants |
| • Androgenic Agents | • Anticonvulsants |
| | • Antidepressant-Other |
| | • Antidepressants- SSRIs |

- Antiemetics
- Antifungals (Oral)
- Antifungals (Topical)
- Antifungals (Vaginal)
- Antihistamines, Minimally Sedating & Combinations
- Antimigraine Agents, CGRPs
- Antimigraine Agents, Triptans
- Antineoplastics- Selected Systemic Enzyme Inhibitors
- Antiparasitics (Topical)
- Antiparkinson's Agents (Oral)
- Antipsychotics
- Antivirals (Oral)
- Antivirals (Topical)
- Aromatase Inhibitors
- Beta Blockers
- Bile Salts
- Bladder Relaxant Preparations
- Bone Resorption Suppression & Related Agents
- BPH Agents
- Calcium Channel Blockers
- Cephalosporins & Related Antibiotics (Oral)
- Colony Stimulating Factors
- Cystic Fibrosis Agents
- Cytokine & Cam Antagonists
- Erythropoiesis Stimulating Proteins
- Fibromyalgia/Neuropathic Pain Agents
- Fluoroquinolones (Oral)
- Gaucher's Disease
- Genital Warts & Actinic Keratosis Agents
- GI Ulcer Therapies
- Growth Hormones
- H. Pylori Combination Treatments
- Hepatitis B Treatments
- Hepatitis C Treatments
- Hereditary Angioedema
- Hyperuricemia & Gout
- Hypoglycemics, Biguanides
- Hypoglycemics, DPP4s and Combinations
- Hypoglycemics, Incretin Mimetics/Enhancers
- Hypoglycemics, Meglitinides
- Hypoglycemics, Sodium Glucose Cotransporter-2 Inhibitors
- Hypoglycemics, TZDs
- Idiopathic Pulmonary Fibrosis
- Immune Globulins
- Immunosuppressive (Oral)
- Intranasal Rhinitis Agents
- Iron Chelating Agents
- IBS/SBS Agents/Selected GI Agents
- Leukotriene Modifiers
- Lipotropics, Other (Non-Statins)
- Lipotropics, Statins
- Miscellaneous Brand/Generic
- Movement Disorder Agents
- Multiple Sclerosis Agents
- Muscular Dystrophy Agents
- NSAIDs
- Ophthalmic Antibiotics
- Ophthalmic Anti-inflammatories
- Ophthalmics for Allergic Conjunctivitis
- Ophthalmics for Dry Eye
- Ophthalmics, Glaucoma Agents
- Otic Antibiotics
- Pancreatic Enzymes
- Parathyroid Agents
- Phosphate Binders
- Platelet Aggregation Inhibitors
- Platelet Stimulating Agents
- Prenatal Vitamins
- Pseudobulbar Affect Agents
- Rosacea Treatments
- Sedative Hypnotics
- Select Contraceptive Products
- Skeletal Muscle Relaxants
- Smoking Deterrents
- Steroids (Topical)
- Tetracyclines
- Ulcerative Colitis & Crohn's Agent

The motion to accept these classes as recommended was made by Dr. Weiland, seconded by Dr. Williamson. Votes were taken and the motion was accepted unanimously.

XI. Extracted Therapeutic Class Reviews

A. Antiretrovirals

Change Healthcare recommended that the following list be approved. A robust clinical discussion followed. Dr. Weiland moved to accept the recommendation. Dr. Davis seconded. Votes were taken, and the motion was adopted. The approved category is as follows:

ANTIRETROVIRALS <small>SmartPA</small>	
SINGLE TABLET REGIMENS	
ATRIPLA (efavirenz/emtricitabine/tenofovir) BIKTARVY (bictegravir/emtricitabine/tenofovir) DELSTRIGO (doravirine/lamivudine/tenofovir) GENVOYA (elvitegravir/cobicistat/emtricitabine/tenofovir) ODEFSEY (emtricitabine/rilpivirine/tenofovir AF) SYMFI (efavirenz/lamivudine/tenofovir) SYMFI-LO (efavirenz/lamivudine/tenofovir)	COMPLERA (emtricitabine/rilpivirine/tenofovir) DOVATO (dolutegravir/lamivudine) JULUCA (dolutegravir/rilpivirine) STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir) SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir) TRIUMEQ (abacavir/lamivudine/ dolutegravir)
PROTEASE INHIBITORS (PEPTIDIC)	
atazanavir EVOTAZ (atazanavir/cobicistat) NORVIR SOLUTION (ritonavir) ritonavir	CRIXIVAN (indinavir) fosamprenavir INVIRASE (saquinavir mesylate) LEXIVA (fosamprenavir) NORVIR POWDER(ritonavir) NORVIR TABLET (ritonavir) REYATAZ (atazanavir) VIRACEPT (nelfinavir mesylate)
PROTEASE INHIBITORS (NON-PEPTIDIC)	
PREZISTA (darunavir ethanolate)	APTIVUS (tipranavir) PREZCOBIX (darunavir/cobicistat)
COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOGS & NON-NUCLEOSIDE RTIs	
ATRIPLA (efavirenz/emtricitabine/tenofovir) CIMDUO (lamivudine/tenofovir) DELSTRIGO (doravirine/lamivudine/tenofovir) ODEFSEY (emtricitabine/rilpivirine/tenofovir AF)	COMPLERA (emtricitabine/rilpivirine/tenofovir)

A. Atopic Dermatitis

Change Healthcare recommended that the following list be approved. A robust clinical discussion followed. Dr. Davis moved to accept the recommendation. Dr. Glenn seconded. Votes were taken, and the motion was adopted. The approved category is as follows:

ATOPIC DERMATITIS <small>SmartPA</small>	
pimecrolimus labeler 68682	DUPIXENT (dupilumab) ELIDEL (pimecrolimus) EUCRISA (crisaborole) pimecrolimus PROTOPIC (tacrolimus) tacrolimus

Dr. Weiland moved to place an electronic Smart PA on Eucrisa to allow grandfathering for users under the age of 18 and a single step thru of a preferred agent, to be determined by the Division of Medicaid. Dr. Hartness seconded. Votes were taken, and the motion failed 1-7.

Dr. Weiland moved to place an electronic Smart PA on Eucrisa to allow a single step thru of a preferred agent, to be determined by the Division of Medicaid. Mr. Rodgers seconded. Votes were taken, and the motion was adopted.

B. Bronchodilators & COPD Agents

Change Healthcare recommended that the following list be approved. A robust clinical discussion followed. Dr. Hartness moved to accept the recommendation. Dr. Weiland seconded. Votes were taken, and the motion was adopted. The approved category is as follows:

BRONCHODILATORS & COPD AGENTS	
ANTICHOLINERGICS & COPD AGENTS	
ATROVENT HFA (ipratropium) ipratropium SPIRIVA HANDIHALER (tiotropium)	DALIRESP (roflumilast) INCRUSE ELLIPTA (umeclidinium) LONHALA MAGNAIR (glycopyrrolate) SEEBRI (glycopyrrolate) SPIRIVA RESPIMAT (tiotropium) TUDORZA PRESSAIR (aclidinium) YUPELRI (revefenacin)

Dr. Maltby moved to place an electronic Smart PA on Spiriva Respimat inhaler for patients 12 and older with an asthma diagnosis to receive the product without a manual PA submission. Dr. Weiland seconded. Votes were taken, and the motion was adopted.

C. Bronchodilators Beta Agonists

Change Healthcare recommended that the following list be approved. A robust clinical discussion followed. Hartness moved to accept the recommendation. Dr. Williamson seconded. Votes were taken, and the motion was adopted. The approved category is as follows:

BRONCHODILATORS, BETA AGONIST	
INHALERS, SHORT-ACTING	
albuterol HFA PROAIR RESPICLICK (albuterol)	PROAIR HFA (albuterol) PROVENTIL HFA (albuterol) VENTOLIN HFA (albuterol) XOPENEX HFA (levalbuterol) SmartPA

D. Factor Deficiency Products

Change Healthcare recommended that the following list be approved. A robust clinical discussion followed. Dr. Weiland moved to accept the recommendation. Dr. Williamson

seconded. Votes were taken, and the motion was adopted. The approved category is as follows:

FACTOR DEFICIENCY PRODUCTS	
FACTOR VIII	
ADVATE AFSTYLA ALPHANATE FEIBA NF HEMOFIL M HUMATE-P KOATE KOATE-DVI KOGENATE FS MONOCLATE-P NOVOEIGHT NUWIQ RECOMBINATE WILATE XYNTHA XYNTHA SOLOFUSE	ADYNOVATE ELOCTATE JIVI KCENTRA KOVALTRY NOVOSEVEN RT OBIZUR VONVENDI
OTHER FACTOR PRODUCTS	
COAGADEX FIBRYGA RIASTAP	CORIFACT HEMLIBRA TRETEN

E. Glucocorticoids (Inhaled)

Change Healthcare recommended that the following list be approved. A robust clinical discussion followed. Dr. Hartness moved to accept the recommendation. Dr. Williamson seconded. Votes were taken, and the motion was adopted. The approved category is as follows:

GLUCOCORTICIDS (Inhaled) ^{SmartPA}	
GLUCOCORTICIDS	
ASMANEX TWISTHALER (mometasone) budesonide 0.25mg and 0.5mg FLOVENT DISKUS(fluticasone) FLOVENT HFA (fluticasone)	AEROSPAN (flunisolide) ALVESCO (ciclesonide) ARMONAIR RESPICLICK (fluticasone) ARNUITY ELLIPTA (fluticasone) ASMANEX HFA (mometasone) budesonide 1mg PULMICORT (budesonide) Respules QVAR (beclomethasone dipropionate)
PULMICORT FLEXHALER (budesonide) QVAR REDIHALER (beclomethasone dipropionate)	
GLUCOCORTICOID/BRONCHODILATOR COMBINATIONS	
ADVAIR HFA (fluticasone/salmeterol) BREO ELLIPTA (fluticasone/vilanterol) DULERA (mometasone/formoterol) fluticasone/salmeterol SYMBICORT (budesonide/formoterol)	ADVAIR DISKUS (fluticasone/salmeterol) AIRDUO Resplick (fluticasone/salmeterol) WIXELA INHUB (fluticasone/salmeterol)

F. Hypoglycemics, Insulins & Related Agents

Change Healthcare recommended that the following list be approved. A robust clinical discussion followed. Dr. Minor moved to accept the recommendation. Dr. Hartness seconded. Votes were taken, and the motion was adopted. The approved category is as follows:

HYPOGLYCEMICS, INSULINS AND RELATED AGENTS <small>SmartPA</small>	
HUMULIN R U500 VIAL (insulin)	AFREZZA (insulin)
insulin aspart	ADMELOG (insulin lispro)
insulin aspart kwikpen	APIDRA (insulin glulisine)
insulin aspart mix	APIDRA SOLOSTAR (insulin glulisine)
insulin aspart mix kwikpen	BASAGLAR (insulin glargine)
insulin lispro	FIASP (insulin aspart)
insulin lispro kwikpen	HUMALOG JR (insulin lispro)
LANTUS SOLOSTAR & VIAL (insulin glargine)	HUMALOG KWIKPEN U100 (insulin lispro)
LEVEMIR FLEXPEN & VIAL (insulin detemir)	HUMALOG KWIKPEN U200 (insulin lispro)
	HUMALOG MIX KWIKPEN (insulin lispro/ lispro protamine)
	HUMALOG MIX VIAL (insulin lispro/ lispro protamine)
	HUMALOG VIAL (insulin lispro)
	HUMULIN KWIKPEN & VIAL* (insulin)
	HUMULIN R U500 KWIKPEN*
	NOVOLOG FLEXPEN & VIAL (insulin aspart)
	NOVOLOG MIX FLEXPEN & VIAL (insulin aspart/ aspart protamine)
	NOVOLIN FLEXPEN (insulin)
	NOVOLIN VIAL (insulin)
	TRESIBA (insulin degludec)
	TOUJEO (insulin glargine)
	TOUJEO MAX (insulin glargine)

G. Opiate Dependence Treatments

Change Healthcare recommended that the following list be approved. A robust clinical discussion followed. Dr. Hartness moved to accept the recommendation. Dr. Williamson seconded. Votes were taken, and the motion was adopted. The approved category is as follows:

OPIATE DEPENDENCE TREATMENTS	
DEPENDENCE	
buprenorphine/naloxone film labeler 52427	buprenorphine tablets
buprenorphine/naloxone tablets	BUNAVAIL (buprenorphine/naloxone)
naltrexone tablets	buprenorphine/naloxone films all other labelers
SUBOXONE FILM (buprenorphine/naloxone) <small>SmartPA</small>	LUCEMYRA (lofexidine)
	PROBUPHINE (buprenorphine)
	SUBLOCADE (buprenorphine)
	VIVITROL (naltrexone)
	ZUBSOLV (buprenorphine/naloxone)

H. Pulmonary Antihypertensives

Change Healthcare recommended that the following list be approved. A robust clinical discussion followed. Dr. Weiland moved to accept the recommendation. Dr. Williamson

seconded. Votes were taken, and the motion was adopted. The approved category is as follows:

PULMONARY ANTIHYPERTENSIVES SmartPA	
ENDOTHELIN RECEPTOR ANTAGONIST	
ambrisentan TRACLEER (bosentan) Tablets	bosentan LETAIRIS (ambrisentan)* OPSUMIT (macitentan) TRACLEER (bosentan) Suspension
PDE5's	
REVATIO (sildenafil) suspension sildenafil (generic Revatio) tablet tadalafil	ADCIRCA (tadalafil) REVATIO (sildenafil) tablet sildenafil (generic Revatio) suspension
PROSTACYCLINS	
	ORENITRAM ER (treprostinil) TYVASO (treprostinil) VENTAVIS (iloprost)

I. Stimulants & Related Agents

Change Healthcare recommended that the following list be approved. A robust clinical discussion followed. Dr. Hartness moved to accept the recommendation for the methylphenidate containing products and Sunosi. Dr. Glenn seconded. Dr. Glenn moved to accept the amphetamine containing products and all other Stimulant and Related Agents. Dr. Weiland seconded. Votes were taken, and the motion was adopted. The approved category is as follows:

STIMULANTS AND RELATED AGENTS SmartPA	
SHORT-ACTING	
amphetamine salt combination dexamethylphenidate IR dextroamphetamine IR METHYLIN chewable tablets (methylphenidate) methylphenidate IR methylphenidate solution PROCENTRA (dextroamphetamine)	ADDERALL (amphetamine salt combination) DESOXYN (methamphetamine) dextroamphetamine solution EVEKEO (amphetamine) EVEKEO ODT (amphetamine) FOCALIN (dexamethylphenidate) methamphetamine METHYLIN solution (methylphenidate) methylphenidate chewable ZENZEDI (dextroamphetamine)
LONG-ACTING	
amphetamine salt combination ER APTENSIO XR (methylphenidate) armodafinil DYANAVEL XR (amphetamine) FOCALIN XR (dexamethylphenidate) methylphenidate CD (generic Metadate CD) methylphenidate ER (generic Concerta) methylphenidate ER Tabs (generic Ritalin SR) modafinil QUILLICHEW (methylphenidate) QUILLIVANT XR (methylphenidate) VYVANSE (lisdexamfetamine)	ADDERALL XR (amphetamine salt combination) ADHANSIA XR (methylphenidate) ADZENYS XR ODT (amphetamine) ADZENYS ER SUSPENSION (amphetamine) CONCERTA (methylphenidate) COTEMPLA XR-ODT (methylphenidate) DAYTRANA (methylphenidate) DEXEDRINE (dextroamphetamine) dexamethylphenidate ER dextroamphetamine ER JORNAY PM (methylphenidate) methylphenidate ER Caps (generic Ritalin LA)

VYVANSE CHEWABLE (lisdexamfetamine)

methylphenidate ER (generic Relexxi)
MYDAYIS (amphetamine salt combination)
NUVIGIL (armodafinil)
PROVIGIL (modafinil)
RELEXXI (methylphenidate)
RITALIN LA (methylphenidate)
RITALIN SR (methylphenidate)
SUNOSI (solriamfetol)

XII. Other Business

No other business

XIII. Division of Medicaid Update

Mrs. Kirby announced that the Division has been hosting pharmacy stakeholder meetings throughout 2019 to discuss the possibility of reimbursing pharmacists for cognitive services. Drew Synder has asked that their presentation be presented at the Medical Care Advisory Committee on November 1, 2019. Mrs. Kirby also announced that the Division has been working to update the State Plan Amendment (SPA) to pay pharmacists an administration fee for giving vaccines rather than a dispensing fee because vaccines are not classified as covered outpatient drugs per Section 1927 of the Social Security Act. This SPA will also address the requirement in Senate Bill 2836 which states, “the division shall allow beneficiaries between the ages of ten and eighteen years to receive vaccines through a pharmacy venue”. This means that pharmacy providers will have to be enrolled in the Vaccines For Children program through the Mississippi State Department of Health in order to administer vaccines to this age group.

XIV. Tentative 2020 Meeting Dates

The proposed 2020 meeting dates of the Pharmacy & Therapeutics Committee are as follows:

- Tuesday, February 18, 2020
- Tuesday, May 12, 2020
- Tuesday, August 11, 2020
- Tuesday, October 27, 2020

Meetings will be held at 9:00 a.m. in the Woolfolk Building, Conference Center East, Room 145, in Jackson, Mississippi.

XV. Adjournment

The meeting adjourned at 12:19p.m.